Medical condition
Pancreatic Cancer
Pancreatic Cancer is a medical condition tracked by NovaPharmaNews across 3 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- erlotinib (ERLOTINIB ARX) Antineoplastic and immunomodulating agents (L01)
- pancreas powder (ENZEPI) Alimentary tract and metabolism (A09)
- masitinib (MASITINIB AB SCIENCE) Antineoplastic and immunomodulating agents (L01)
Clinical pipeline & programs
Explore Oncology drug development programs tracked across clinical phases.
Latest Pancreatic Cancer news
FDA Accepts Daraxonrasib NDA for Pancreatic Cancer
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.
Pancreatic Cancer New Treatment 2026: Daraxonrasib
Pancreatic cancer new treatment 2026 conversations now center on daraxonrasib, an oral RAS(ON) multi-selective inhibitor. In Phase 3 RASolute 302, median overall survival nearly doubled versus investigator-choice chemotherapy in previously treated metastatic PDAC.
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
Revolution Medicines’ daraxonrasib nearly doubled median survival in a Phase 3 trial for pancreatic cancer, offering a new standard of care. This article analyzes the clinical data, side effect profile, and competitive implications for pharma teams.
Revolution Medicine Pancreatic Cancer Access Strain
Revolution Medicines' daraxonrasib has shown a dramatic overall survival benefit in pancreatic cancer, but patient demand is overwhelming the expanded access program. For pharma strategists, the supply-demand imbalance signals potential launch revenue upside and commercial execution risk.
Pancreatic Cancer Drug Shows Phase 3 Survival Gain
Structured plan for Experimental pancreatic cancer drug offers new hope in major trial
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Structured plan for FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer